Shares of DexCom Inc. DXCM slipped 1.04% to $69.70 Monday, on what proved to be an all-around positive trading session for ...

Ypsomed reports positive outcomes from a randomized trial of its closed-loop insulin delivery technology during type 1 ...

More than a decade after coining “Treat Yo’ Self Day” in her role as Donna on “Parks & Recreation,” Retta is once again ...

Tandem Diabetes TNDM is gaining from continued product innovations. Yet, ongoing macroeconomic challenges and tough ...

Wells Fargo analyst Larry Biegelsen maintained a Buy rating on Dexcom (DXCM – Research Report) yesterday and set a price target of ...

No pain, no gain,” that’s what Trivariate Research, a U.S. equity focused research house, highlighted about stocks that have ...

Shares of DexCom Inc. DXCM slid 2.07% to $70.43 Friday, on what proved to be an all-around mixed trading session for the ...

DexCom's revised FY24 sales guidance in the Q2 earnings call led to a $18bn valuation reset. Read why I think DXCM stock is a ...

DexCom Inc (DXCM) stock saw a decline, ending the day at $68.94 which represents a decrease of $-1.15 or -1.64% from the prior close of $70.09. The stock opened at $69.99 and touched a low of $68.59 ...

Real-world data showed reductions in healthcare resource utilization and improved glycemic control over 1 year with ...

DexCom, Inc. (NASDAQ: DXCM), the global leader in real-time continuous glucose monitoring (CGM) for people with diabetes, announced today the launch of the third season of Dexcom U, the company's ...